Q-omics provides the consensus-scored RN7SL668P profile across patient tissues and cancer cell-line models. RN7SL668P expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, RN7SL668P is differentially expressed in 4, with the highest sampling consensus in KIRC. Additionally, RN7SL668P RNA expression shows 6,896 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight COAD, KIRC, and THYM as cancer lineages where RN7SL668P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RN7SL668P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RN7SL668P survival associations across molecular data types. RN7SL668P RNA expression shows survival associations in the most cancer types (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RN7SL668P RNA expression–survival associations across cancer types. High RN7SL668P expression shows unfavorable associations in COAD, SKCM, BRCA and SARC, but favorable associations in THCA and UCEC. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .012). Together, the overview and detailed table identify COAD as the clearest survival context for RN7SL668P RNA expression.
This table summarizes RN7SL668P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RN7SL668P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RN7SL668P shows lower tumor expression in KIRC, KICH and KIRP and higher tumor expression in LIHC. The KIRC box plot shows higher RN7SL668P RNA expression in normal versus tumor tissue (log2 FC = −0.232, t-test p < 0.001).
This table shows molecular features associated with RN7SL668P in patient tissues and cancer cell lines. In patient samples, RN7SL668P shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
